SG11202100580UA - Treatment of chronic cough, breathlessness and dyspnea - Google Patents

Treatment of chronic cough, breathlessness and dyspnea

Info

Publication number
SG11202100580UA
SG11202100580UA SG11202100580UA SG11202100580UA SG11202100580UA SG 11202100580U A SG11202100580U A SG 11202100580UA SG 11202100580U A SG11202100580U A SG 11202100580UA SG 11202100580U A SG11202100580U A SG 11202100580UA SG 11202100580U A SG11202100580U A SG 11202100580UA
Authority
SG
Singapore
Prior art keywords
breathlessness
dyspnea
treatment
chronic cough
cough
Prior art date
Application number
SG11202100580UA
Inventor
Thomas Sciascia
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of SG11202100580UA publication Critical patent/SG11202100580UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11202100580UA 2018-07-23 2019-07-23 Treatment of chronic cough, breathlessness and dyspnea SG11202100580UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862701902P 2018-07-23 2018-07-23
PCT/US2019/042994 WO2020023486A1 (en) 2018-07-23 2019-07-23 Treatment of chronic cough, breathlessness and dyspnea

Publications (1)

Publication Number Publication Date
SG11202100580UA true SG11202100580UA (en) 2021-02-25

Family

ID=69162461

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100580UA SG11202100580UA (en) 2018-07-23 2019-07-23 Treatment of chronic cough, breathlessness and dyspnea

Country Status (12)

Country Link
US (3) US20200022974A1 (en)
EP (1) EP3826635A4 (en)
JP (1) JP2021531299A (en)
KR (1) KR20210035854A (en)
CN (1) CN112703000A (en)
AU (1) AU2019309913A1 (en)
BR (2) BR122023024228A2 (en)
CA (1) CA3106995A1 (en)
IL (1) IL280301A (en)
MX (1) MX2021000908A (en)
SG (1) SG11202100580UA (en)
WO (1) WO2020023486A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3106995A1 (en) 2018-07-23 2020-01-30 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness, or dyspnea with nalbuphine compositions
WO2021142288A1 (en) * 2020-01-10 2021-07-15 Trevi Therapeutics, Inc. Methods of administering nalbuphine

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443442A (en) 1979-12-21 1984-04-17 Skillern Scott D Method and composition for treatment of acne vulgaris
AU8952282A (en) 1982-08-25 1984-03-29 Joel E. Bernstein Method of treating pruritis and composition therefor
US4720384A (en) 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
US20010006967A1 (en) 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
DE69737592T2 (en) 1996-11-25 2008-01-03 Toray Industries, Inc. MEDIUM AGAINST JUCKREIZ
US6787149B1 (en) 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
IL132363A (en) 1997-07-14 2004-02-19 Adolor Corp Kappa agonist compounds for use in the prevention or treatment of pruritus and anti-pruritic pharmaceutical formulations containing them
US5760023A (en) 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
CN101518653B (en) 1999-06-25 2015-08-19 基因技术股份有限公司 Use the Therapeutic Method of anti-ErbB antibody-maytansinoid conjugate
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
JP2001163784A (en) 1999-12-06 2001-06-19 Toray Ind Inc Antipruritic for cornea or conjunctiva
DE19960154A1 (en) * 1999-12-14 2001-07-12 Lohmann Therapie Syst Lts Flat pharmaceutical preparation for transmucosal administration of oxycodone or a comparable active ingredient in the oral cavity, for use in pain therapy and addiction therapy
JP4370683B2 (en) 2000-05-08 2009-11-25 東レ株式会社 Testing method for pruritic diseases
DE10116978A1 (en) 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa opiate agonists for the treatment of diseases of the bladder
ITMI20010907A1 (en) 2001-05-02 2002-11-02 Valpharma Sa USE OF OPIOID ANTAGONISTS FOR THE PREVENTION AND CONTROL OF THE SIDE EFFECTS PRODUCED BY THE OPIOIDS
US20030054030A1 (en) 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
PT1436012T (en) 2001-10-18 2018-03-27 Nektar Therapeutics Polymer conjugates of opioid antagonists
US6703398B2 (en) 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP4620355B2 (en) 2002-04-05 2011-01-26 ユーロ−セルティーク エス．エイ． Matrix for sustained, constant and independent release of active compounds
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
DE10229842A1 (en) 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinane derivatives and their quaternary ammonium salts substituted in position 14, production process and use
SI1585966T1 (en) 2002-07-15 2012-02-29 Hoffmann La Roche Treatment of cancer with the anti-ErbB2 antibody rhuMAb 2C4
ES2376165T3 (en) 2002-07-15 2012-03-09 F. Hoffmann-La Roche Ag TREATMENT OF THE C�? NCER WITH THE ANTIBODY DIRECTED AGAINST ERBB2 RHUMAB 2C4.
US7381721B2 (en) 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
US7459146B2 (en) 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
WO2005032555A2 (en) 2003-09-25 2005-04-14 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
WO2005094826A1 (en) 2004-03-30 2005-10-13 Toray Industries, Inc. Anti-itching agent
EP1763349A2 (en) 2004-06-03 2007-03-21 Jonathan J. Burbaum Pharmaceutical compositions for the treatment of pruritus
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
AR057325A1 (en) 2005-05-25 2007-11-28 Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057035A1 (en) 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
NZ563373A (en) 2005-06-09 2012-06-29 Meda Ab Method and composition for treating inflammatory disorders
US8394812B2 (en) * 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
ES2441766T3 (en) * 2005-08-24 2014-02-06 Endo Pharmaceuticals Inc. Sustained-release nalbuphine formulations
US20070060501A1 (en) 2005-08-30 2007-03-15 Khem Jhamandas Methods and therapies for potentiating a therapeutic action of an opioid receptor agonist and inhibiting and/or reversing tolerance to opioid receptor agonists
JP2009528264A (en) 2006-01-10 2009-08-06 ザイモジェネティクス，インコーポレイティド Methods for treating pain and inflammation in neural tissue using IL-31 antagonists
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
JP2008109898A (en) 2006-10-31 2008-05-15 Toray Ind Inc Method for screening compound having antipruritic activity
BRPI0718651B8 (en) 2006-11-10 2021-05-25 Cara Therapeutics Inc synthetic peptide amides
JP2010510328A (en) 2006-11-22 2010-04-02 プロジェニックス ファーマスーティカルス インコーポレーテッド (R) -N-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
MX2009005460A (en) 2006-11-22 2009-08-28 Progenics Pharm Inc (s)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs.
CA2670342A1 (en) 2006-11-22 2008-06-12 Progenics Pharmaceuticals, Inc. N-oxides of 4,5-epoxy-morphinanium analogs
US20080207667A1 (en) * 2007-02-23 2008-08-28 Rhame Robert W Use of nalbuphine and related compounds to treat symptoms of respiratory problems
WO2008121348A2 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
CN101677997B (en) 2007-03-30 2012-05-09 泰奥加制药公司 Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
TW200902014A (en) 2007-04-20 2009-01-16 Novartis Ag Uses of vanilloid receptor antagonists
US8476318B2 (en) 2007-04-23 2013-07-02 Symrise Ag Polyethylene glycol esters and cosmetic and/or dermatological preparations
WO2009000878A1 (en) 2007-06-28 2008-12-31 Novartis Ag Kallikrein 7 modulators
EP2197427A2 (en) 2007-09-04 2010-06-23 Alpharma, Inc. A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
US20090093509A1 (en) 2007-10-08 2009-04-09 Tahir Nazir Methods and Compositions for the Treatment of Pruritus
WO2009070733A1 (en) 2007-11-26 2009-06-04 Pharmacofore, Inc. Peripheral phenolic opioid antagonist
TR201809734T4 (en) 2008-02-14 2018-07-23 Alkermes Inc Selective opioid compounds.
US8686040B2 (en) 2008-03-31 2014-04-01 Rdd Pharma Ltd. Method for treating anal pruritis and other perianal disorders
WO2009132313A2 (en) 2008-04-25 2009-10-29 Progenics Pharmaceuticals, Inc. Morphinan derivatives of organic and inorganic acids
CA2740440A1 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis-associated pulmonary fibrosis
KR20110118830A (en) 2009-02-24 2011-11-01 노파르티스 아게 Uses of nk receptor antagonists
US20100227876A1 (en) 2009-03-06 2010-09-09 Rechfensen Llp Methods of Reducing Side Effects of Analgesics
AU2009342654B2 (en) 2009-03-19 2013-09-05 Alkermes Pharma Ireland Limited Morphinan derivatives with high oral bioavailability
AU2010238925A1 (en) 2009-04-22 2011-12-15 Phoeme Gmbh Particulate pharmaceutical composition having an opioid and an opioid antagonist
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
US9364623B2 (en) * 2009-07-15 2016-06-14 UNIVERSITé LAVAL Method and device for administering oxygen to a patient and monitoring the patient
US10131672B2 (en) 2010-01-29 2018-11-20 Toray Industries, Inc. Therapeutic or prophylactic agent for biliary diseases
IT1398930B1 (en) 2010-03-24 2013-03-28 Molteni & C PHARMACEUTICAL FORMULATIONS BISTRATO CONTAINING OPPOSING AGONISTS AND ANTAGONISTS.
FR2963889B1 (en) * 2010-08-20 2013-04-12 Debregeas Et Associes Pharma NALBUPHINE-BASED FORMULATIONS AND USES THEREOF
JP2012087101A (en) 2010-10-21 2012-05-10 Holger Hermann Lars Particulate pharmaceutical composition containing opioid and opioid antagonist
CN110585209A (en) 2012-12-14 2019-12-20 特雷维治疗股份有限公司 Method for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
WO2015027212A1 (en) * 2013-08-23 2015-02-26 Afferent Pharmaceuticals Inc. Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
WO2015192071A1 (en) 2014-06-13 2015-12-17 Trevi Therapeutics, Inc. Methods for treating pruritus
TW201735914A (en) * 2015-12-22 2017-10-16 阿斯特捷利康公司 Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
KR102647744B1 (en) * 2015-12-23 2024-03-14 콘리그 파마 에이피에스 Tosyl Acid Suplatast for the treatment of cough associated with interstitial lung disease
US20170216277A1 (en) 2016-01-06 2017-08-03 Trevi Therapeutics, Inc. Therapeutic use of nalbuphine without aquaretic effects
CN113274392A (en) * 2016-01-08 2021-08-20 尼尔医疗有限公司 Orvipitan for treating chronic cough
CN105560202B (en) 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 A kind of preparation method and application of nalbuphlne hydrochloride gel skeleton sustained release tablets
CA3017374A1 (en) 2016-03-21 2017-09-28 Trevi Therapeutics, Inc. Treatment of uremic pruritus
CN109475626A (en) * 2016-07-14 2019-03-15 儿童医院医疗中心 The method for treating fibrosis
EP3506893A4 (en) * 2016-08-31 2020-01-22 Respivant Sciences GmbH Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
EP3532061A4 (en) 2016-10-25 2020-07-08 Trevi Therapeutics, Inc. Treatment of prurigo nodularis
CN112672743A (en) 2018-07-11 2021-04-16 特雷维治疗股份有限公司 Treatment of pruritus symptoms of liver disease
CA3106995A1 (en) 2018-07-23 2020-01-30 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness, or dyspnea with nalbuphine compositions

Also Published As

Publication number Publication date
WO2020023486A1 (en) 2020-01-30
US20220218697A1 (en) 2022-07-14
EP3826635A1 (en) 2021-06-02
MX2021000908A (en) 2021-06-08
IL280301A (en) 2021-03-01
JP2021531299A (en) 2021-11-18
BR112021001177A2 (en) 2021-04-27
EP3826635A4 (en) 2022-04-27
AU2019309913A1 (en) 2021-03-11
CA3106995A1 (en) 2020-01-30
CN112703000A (en) 2021-04-23
BR122023024228A2 (en) 2024-02-20
US20200022974A1 (en) 2020-01-23
US20220409613A1 (en) 2022-12-29
KR20210035854A (en) 2021-04-01
US11660296B2 (en) 2023-05-30

Similar Documents

Publication Publication Date Title
IL269026A (en) Methods of treating tumor
ZA202006746B (en) Methods of treatment
EP3454945A4 (en) Ash1l inhibitors and methods of treatment therewith
ZA201907168B (en) Methods of treating doose syndrome using fenfluramine
IL274865A (en) Methods of treatment with asparaginase
ZA201808607B (en) Methods of treating prader-willi syndrome
EP3706737A4 (en) Ash1l inhibitors and methods of treatment therewith
EP3313186A4 (en) Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment
HUE045764T2 (en) Orvepitant for the treatment of chronic cough
GB201706406D0 (en) Method of treatment
IL264804B (en) Regimens and methods of treating multiple sclerosis using ofatumumab
GB201815588D0 (en) Method of treatment
IL280301A (en) Treatment of chronic cough, breathlessness and dyspnea
EP3961945C0 (en) Decoding methods and apparatuses
GB201817198D0 (en) Treatment ported sub and method of use
SG11202105877YA (en) Method of treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
IL283912B (en) Methods of treating cancer using platanoside and isomers thereof
IL290983A (en) Methods of treatment
GB201918853D0 (en) Methods of treatment
GB201821093D0 (en) Treatment of hydrocarbons
GB201900942D0 (en) Methods of treatment
GB201801249D0 (en) Methods of treatment
GB201820236D0 (en) Method of treatment
GB201820157D0 (en) Method of treatment